Foghorn Therapeutics/$FHTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Foghorn Therapeutics
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
- Ticker
- $FHTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 106
- Headquarters
- Watertown, United States
- Website
- foghorntx.com
FHTX Metrics
BasicAdvanced
$209M
-
-$0.97
2.84
-
Price and volume
Market cap
$209M
Beta
2.84
52-week high
$7.61
52-week low
$3.27
Average daily volume
445K
Financial strength
Current ratio
3.362
Quick ratio
3.313
Long term debt to equity
-0.497
Total debt to equity
-0.532
Profitability
EBITDA (TTM)
-66.353
Gross margin (TTM)
-114.57%
Net profit margin (TTM)
-175.78%
Operating margin (TTM)
-186.38%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-19.92%
Return on equity (TTM)
81.90%
Valuation
Price to revenue (TTM)
6.378
Price to book
-2.55
Price to tangible book (TTM)
-2.55
Price to free cash flow (TTM)
-2.78
Free cash flow yield (TTM)
-35.97%
Free cash flow per share (TTM)
-1.266
Growth
Revenue change (TTM)
51.98%
Earnings per share change (TTM)
-19.12%
3-year revenue growth (CAGR)
19.14%
3-year earnings per share growth (CAGR)
-29.29%
What the Analysts think about FHTX
Analyst ratings (Buy, Hold, Sell) for Foghorn Therapeutics stock.
Analyst projections of the future price of Foghorn Therapeutics stock.
FHTX Financial Performance
Revenues and expenses
FHTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing FHTX
AllUSDGBPEUR
Fund name | Fund size | $FHTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.